Authors
Latest:
Pluvicto Approval Launches Theranostics in Prostate CancerAshok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.
Latest:
Combination of Venetoclax and Hypomethylating Agents Show Efficacy in AMLDanielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.
Latest:
Post–COVID-19 Infection Remains a Concern in Patients With CancerMany questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Latest:
Investigating KRAS/TP53 Co-Alterations in Pancreatic CancerJashodeep Datta, MD, explains KRAS and TP53 co-alterations in patients with pancreatic cancer.
Latest:
Optimizing the Management of Melanoma: Future Directions in CareClosing out his discussion on the management of metastatic melanoma, expert oncologist Sajeve Thomas, MD, summarizes unmet needs and looks toward future evolutions in the treatment paradigm.
Latest:
The Future of Neoadjuvant Immunotherapy in MIBCDr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.
Latest:
Experts Compare Available Regimens for a Patient With Sarcomatoid FeaturesDuring a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.
Latest:
Adapting to Second-Line Restrictions of Niraparib in Ovarian CancerThe approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.
Latest:
Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLCThe panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
Latest:
Higher MRD Threshold Could Guide Discontinuation of Myeloma MaintenanceBen Derman, MD, discussed results from a trial investigating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.
Latest:
NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKIExpert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Latest:
Biomarkers in Renal Cell Carcinoma: Present Utility and Future PossibilityWenxin (Vincent) Xu, MD, provides insight on biomarkers in renal cell carcinoma.
Latest:
ENDOLA Study Demonstrates Promise of Olaparib Triplet in Endometrial CancerAn olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.
Latest:
Ovarian Cancer Awareness Month: Strides in Up-front and Maintenance TherapyGizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.
Latest:
Utilizing MRD Testing in the Myeloma SpaceGayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.
Latest:
Exploring Ongoing Trials With 177Lu-PSMA-617 in Prostate CancerArun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.
Latest:
First-Line Osimertinib Displays Comparable Survival Outcomes Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLCNew results from the phase 2 APPLE trial shows how the use of osimertinib in the upfront setting compares with combination therapy in patients with EGFR-positive non–small cell lung cancer.
Latest:
Remote Monitoring Improves Management of Symptoms in Patients With Lung Cancer After SurgeryBrett Simon, MD, PhD, discusses an ongoing program at his institution that aims to improve symptoms and outcomes for patients with lung cancer who have undergone surgery.
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
Future Directions and Unmet Needs in T-ALLBijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
Excitement Shown With CDK4/6 Inhibitors and More in Breast Cancer ResearchSeth Wander, MD, PhD, discusses what research and topics excite him when looking to further evaluate future treatments for patients with breast cancer.
Latest:
Pandemic Leads to Delays in Crucial Early Cancer Screening TestsClayton Lau, MD, discusses the consequences of patients delaying cancer screenings due to fears of COVID-19.
